PE-backed Galantos Pharma sells Alzheimer's drug

Memogain will be ready to start in clinical trials in late 2013.

Neurodyn is a biotechnology firm based in Canada. It focuses on treatments for neurological conditions.

In 2010, Galantos Pharma secured €4.4m in a series-C funding round by Rhineland Palatinate Fund VRP, German state bank KfW, Investment Bank Rhineland FIB, Venture Fund Rhineland Palatinate WFT, High-Tech Gründerfonds and the German Ministry for Education and Research.

Galantos Pharma was founded in 2005. The firm conducts research in the natural compound synthesis, molecular medicine and neuro-pharmacology sectors. It develops pharmaceuticals for the central nervous system.

Kenneth Cawkell is Neurodyn's CEO. Alfred Maelicke is the founder and CEO of Galantos Pharma. Caroline Fichtner is senior investment manager at HTGF.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• DACH
• Portfolio management
• Germany
• High-Tech Gründerfonds